Theseus Pharmaceuticals

Theseus Pharmaceuticals

  • Founded: 2017
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: NSCLC
  • Drug types: ONC
  • Lead product: THE-349
  • Product link:
  • Funding: $160M IPO Oct 2021; $100M B Apr 2021

job board

Short description:

Kinase Inhibitors

Drug notes:

undisclosed RD cancers

Long description:

Theseus Pharmaceuticals is designing kinase inhibitors for targeted cancer treatments. Cancer resistance occurs when cancerous cells mutate to circumvent the effect of a therapeutic. Resistance is commonly seen in therapies that target protein kinases. Theseus is outsmarting cancer resistance by developing next-generation tyrosine kinase inhibitors that offer more effective ways to treat cancer. Theseus’ approach involves using their unique drug discovery platform to develop pan-variant tyrosine kinase inhibitor therapies that uses chemical structure analyses with biomarker-guided design. Theseus’ lead candidate inhibitor, THE-630, has the potential to generate a robust and durable response in patients with gastrointestinal stromal tumors.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy